Insider Selling: Werewolf Therapeutics (NASDAQ:HOWL) Director Sells 107,429 Shares of Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 107,429 shares of Werewolf Therapeutics stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $0.31, for a total transaction of $33,302.99. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Luke Evnin also recently made the following trade(s):

• On Monday, July 6th, Luke Evnin sold 35,770 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.32, for a total value of $11,446.40.
• On Tuesday, June 9th, Luke Evnin sold 76,928 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.37, for a total value of $28,463.36.
• On Monday, June 8th, Luke Evnin sold 60,547 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.40, for a total transaction of $24,218.80.
• On Friday, June 5th, Luke Evnin sold 24,946 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.40, for a total value of $9,978.40.
• On Thursday, June 4th, Luke Evnin sold 20,072 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.44, for a total value of $8,831.68.
• On Wednesday, June 3rd, Luke Evnin sold 29,749 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.42, for a total transaction of $12,494.58.
• On Tuesday, June 2nd, Luke Evnin sold 29,595 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.45, for a total transaction of $13,317.75.
• On Monday, June 1st, Luke Evnin sold 80,459 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.47, for a total value of $37,815.73.
• On Friday, May 29th, Luke Evnin sold 32,556 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.45, for a total transaction of $14,650.20.
• On Thursday, May 28th, Luke Evnin sold 27,698 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.46, for a total value of $12,741.08.

Werewolf Therapeutics Price Performance

Shares of NASDAQ:HOWL traded up $0.02 during trading hours on Wednesday, hitting $0.36. The company’s stock had a trading volume of 590,804 shares, compared to its average volume of 539,946. The firm’s fifty day moving average price is $0.46 and its 200 day moving average price is $0.63. Werewolf Therapeutics, Inc. has a 52 week low of $0.27 and a 52 week high of $2.38. The company has a market capitalization of $17.49 million, a price-to-earnings ratio of -0.29 and a beta of 0.30.

Werewolf Therapeutics (NASDAQ:HOWL) last posted its earnings results on Thursday, May 7th. The company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.04. On average, equities research analysts predict that Werewolf Therapeutics, Inc. will post -1.08 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

HOWL has been the subject of a number of recent analyst reports. Wall Street Zen cut Werewolf Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Weiss Ratings downgraded shares of Werewolf Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 16th. Two investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $3.75.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the company. Bank of America Corp DE increased its stake in Werewolf Therapeutics by 1.2% during the second quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock worth $2,321,000 after purchasing an additional 25,882 shares during the period. Vanguard Group Inc. raised its position in Werewolf Therapeutics by 8.5% in the 3rd quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock valued at $2,774,000 after purchasing an additional 109,796 shares in the last quarter. Renaissance Technologies LLC boosted its stake in shares of Werewolf Therapeutics by 48.6% in the 4th quarter. Renaissance Technologies LLC now owns 677,766 shares of the company’s stock valued at $429,000 after buying an additional 221,766 shares during the period. Jane Street Group LLC purchased a new position in Werewolf Therapeutics in the second quarter worth approximately $409,000. Finally, Citadel Advisors LLC purchased a new position in Werewolf Therapeutics in the third quarter worth approximately $304,000. 64.84% of the stock is currently owned by institutional investors and hedge funds.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.